The largest trial involving DSIP to date, which included a total of 107 volunteers, reported that the peptide was generally well-tolerated with mostly minor side effects, which included [8]: Low blood pressure Increased sweating Headache Nausea Vertigo Considering that the drop in blood pressure was reported as moderate to severe in some patients, researchers should consider hypotension as a potentially exclusionary criterion for DSIP research
The material below is summarised strictly for research-use-only (RUO) context and is not medical advice, nor a dosing guide, nor a suggestion that either compound is safe or effective in people
Their activation and incorporation into phospholipids are orchestrated by acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3), two critical regulators of ferroptosis (Dixon et al., 2015
Injectable peptides such as BPC-157, TB-500, and GLP-1 analogs are largely research compounds or prescription-only medicines